We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Findings May Lead to Enhanced Treatments for Multiple Sclerosis and Autoimmune Inflammation

By LabMedica International staff writers
Posted on 10 Dec 2014
A multidisciplinary research team of scientists from Singapore has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS).

Led by Prof. More...
Xin-Yuan Fu, senior lead investigator from CSI Singapore and professor at the department of biochemistry at the National University of Singapore (NUS) Yong Loo Lin School of Medicine (Singapore), and Dr. Wanqiang Sheng, postdoctoral fellow at CSI Singapore, the scientists discovered that a new type of immune T helper cells called TH-GM cells play a crucial role in the immune system and pathogenesis of neuronal inflammation. The findings offer insights into a potential new avenue for therapeutic intervention, which can be used independently or combined with other treatment options to optimize outcomes in the treatment of MS.

Working with Dr. Yong-Liang Zhang, from the department of microbiology at the NUS Yong Loo Lin School of Medicine, Prof. Fu and his team demonstrated that STAT5, a member of the STAT family of proteins, programs TH-GM and triggers the immune response to an autoantigen in responding to a signal from an interleukin, IL-7, causing neuroinflammation, pathogenesis and damage in the central nervous system. Blocking IL-7 or STAT5 would provide a substantial therapeutic benefit for this disease. The study’s findings were published online November 21, 2014, in the journal Cell Research.

MS is the most prevalent autoimmune disease of the central nervous system, affecting about 2.5 million people worldwide, with cases showing a higher prevalence in Northern Europe. In spite of many years of research, the causes of MS are mostly not known and the disease remains incurable.

This study provides vital clues into the processes behind MS. Dr. Richard Flavell, chair of the department of immunology at Yale University (New Haven, CT, USA), and a world leader in the immunology field, noted that the findings from the study may now provide a mechanistic link between IL-7/STAT5-mediated signaling and T helper cell-mediated pathogenicity.

The STAT family of proteins and their signaling pathway (called JAK-STAT) were first discovered by Prof. Fu and his colleagues in 1992. Disturbance of this pathway was shown to be a major cause for many kinds of inflammatory disorders. Innovative drugs interfering with JAK-STAT have since been approved in the United States, Europe, and Singapore for the treatment of numerous diseases, and annual sales of medicines involving JAK-STAT are expected to exceed USD 1.6 billion in 2016. The newly discovered IL-7-STAT5 by Prof. Fu and his team in neuroinflammation considerably expands this line of medical research, development, and therapeutic intervention in a variety of major diseases.

Prof. Fu and collegues are now researching the physiologic function of TH-GM to further the development of therapy for various human autoimmune diseases.

Related Links:

CSI Singapore
National University of Singapore Yong Loo Lin School of Medicine



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.